Contact Us

We are committed to the professional and patient communities we serve. In the spirit of this commitment, we invite ongoing feedback
and dialogue.

CORPORATE INFORMATION

Lantheus
331 Treble Cove Rd.
N. Billerica, MA 01862

Phone: 1-800-362-2668

CUSTOMER SERVICE

US Customer Service/Order PYLARIFY®

Phone: 1-800-964-0446

Hours: 8:30 am to 8:00 pm ET, Monday to Friday

PYLARIFY® REIMBURSEMENT RESOURCES

Call Toll Free: 844-339-8514

Lantheus cannot guarantee coverage or payment for products or procedures. Payer policies can vary widely and third party payment for medical products and services is affected by numerous factors. It is always the provider’s responsibility to determine and submit appropriate codes, charges, and modifiers for services rendered. For more specific information, contact your third-party payer directly in order to obtain up-to-date coverage, coding, and payment information.

ADVERSE EVENT AND PRODUCT QUALITY COMPLAINT REPORTS

Adverse Events and Product Quality Complaint Reports must be reported through the following channels:

Phone: 1-800-343-7851
Press Option 2 for Adverse Events
Press Option 2 for Product Quality Complaints

Fax: 978-436-7296

Email: lantheussafety@lantheus.com

MEDICAL INFORMATION

For adverse events and product quality complaints, please use contact information above.

Phone: 1-800-343-7851 (Outside US: 978-667-9531)
Press Option 3, followed by
Option 1, for Medical Information

Fax: 978-671-8736

Hours: 8:30 am to 5:00 pm ET, Monday to Friday

Email: medicalinformation@lantheus.com

SALES

If you would like a sales representative to contact you, please complete the form below.

CONTACT FORM

*Please complete the required fields below.

INDICATION

PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Reference

  1. FDA approval letter for aPROMISE. Food and Drug Administration. July 27, 2021.